For research use only. Not for therapeutic Use.
GBR-12935 is a potent and selective dopamine reuptake inhibitor. It was originally developed in its 3H radiolabelled form for the purpose of mapping the distribution of dopaminergic neurons in the brain by selective labelling of dopamine transporter proteins. This has led to potential clinical uses in the diagnosis of Parkinson/’s disease, although selective radioligands such as Ioflupane (¹²³I) are now available for this application. GBR-12935 is now widely used in animal research into Parkinson/’s disease and the dopamine pathways in the brain.
| Catalog Number | I006936 |
| CAS Number | 67469-81-2 (HCl) |
| Synonyms | GBR12935; GBR 12935; GBR-12935; GBR-12935 HCl; GBR-12935 hydrochloride;1-(2-(benzhydryloxy)ethyl)-4-(3a-phenylpropyl)piperazine dihydrochloride |
| Molecular Formula | C28H36Cl2N2O |
| Purity | ≥95% |
| Target | Dopamine Transporter |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| IUPAC Name | 1-(2-benzhydryloxyethyl)-4-(3-phenylpropyl)piperazine;dihydrochloride |
| InChI | InChI=1S/C28H34N2O.2ClH/c1-4-11-25(12-5-1)13-10-18-29-19-21-30(22-20-29)23-24-31-28(26-14-6-2-7-15-26)27-16-8-3-9-17-27;;/h1-9,11-12,14-17,28H,10,13,18-24H2;2*1H |
| InChIKey | NQWRSILGEXNJIT-UHFFFAOYSA-N |
| SMILES | C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=CC=C3)C4=CC=CC=C4.Cl.Cl |
| Reference | </br>1:Zhu J, Green T, Bardo MT, Dwoskin LP. Environmental enrichment enhances sensitization to GBR 12935-induced activity and decreases dopamine transporter function in the medial prefrontal cortex. Behav Brain Res. 2004 Jan 5;148(1-2):107-17. PubMed PMID: 14684252. |
